CLDX | Ticker Profile - Titan Protect

CLDX

Celldex Therapeutics, Inc.

Healthcare · Biotechnology · NCM

$28.62

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$2.5B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-6.96

Based on estimated future earnings — lower means cheaper

Rev Growth

-97.8%

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

-48.9%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$58.00

+103% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 14 analysts covering this stock

About Celldex Therapeutics, Inc.

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.

https://www.celldex.com

Country: United States Employees: 198 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.216

Positive but modest risk-adjusted returns

Kelly Fraction

0.0171

Marginal edge — very small allocation suggested

Calmar Ratio

-0.057

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-3.8%

Historical annualised return based on price data

Max Drawdown

-66.1%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.98

Less volatile than the market — more defensive

52W High

$35.79

20% below the year high

52W Low

$18.55

54% above the year low

Avg Volume

975,345

Average daily shares traded — higher means easier to buy and sell

Short Ratio

9.1

Days it would take all short sellers to cover — higher means more crowded

Short % Float

10.8%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-4.27

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

0.42

Conservative use of debt — low financial risk

Current Ratio

8.92

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

8.78

Like current ratio but excludes inventory — stricter test

Gross Margin

0.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-562,900.0%

Profit from core operations before interest and tax

Free Cash Flow

$-126,271,376

Negative — the business is spending more than it generates

Revenue (TTM)

$865,000

Total revenue over the last 12 months

Net Income

$-283,646,016

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$90.00

Target Median

$58.00

Target Low

$38.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go